Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yutian Feng

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
International Journal of Nanomedicine|November 5, 2021
Gold Nanostars: A Novel Platform for Developing <sup>211</sup>At-Labeled Agents for Targeted Alpha-Particle TherapyYang Liu, Zhengyuan Zhou, Yutian Feng, et al.
Microbiology Resource Announcements|April 3, 2019
Complete Genome Sequence of Halorubrum ezzemoulense Strain Fb21Yutian Feng, Artemis S Louyakis, Andrea M Makkay, et al.
Mbio|April 15, 2024
Using the pan-genomic framework for the discovery of genomic islands in the haloarchaeon <i>Halorubrum ezzemoulense</i>Yutian Feng, Danielle Arsenault, Artemis S Louyakis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 30, 2025
Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [<sup>211</sup>At]YF2Yutian Feng, Truc T Huynh, Yongxiang Zheng, et al.
Nuclear Medicine and Biology|May 4, 2024
PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranosticsTruc T Huynh, Yutian Feng, Rebecca Meshaw, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 10, 2026
First-in-human evaluation of [<sup>211</sup>At]YF2 in patients with metastatic castration-resistant prostate cancerXiaoai Wu, Yongzhao Xiang, Michael R Zalutsky, et al.
Journal of Medicinal Chemistry|November 11, 2022
Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic AgentYutian Feng, Samantha M Sarrett, Rebecca L Meshaw, et al.
Nuclear Medicine and Biology|May 4, 2024
A third generation PSMA-targeted agent [<sup>211</sup>At]YF2: Synthesis and in vivo evaluationYutian Feng, Rebecca L Meshaw, Sean W Finch, et al.
Exploration (Beijing, China)|March 5, 2025
Bioactive scaffolds for tissue engineering: A review of decellularized extracellular matrix applications and innovationsJuan Liu, Qingru Song, Wenzhen Yin, et al.
Molecular Pharmaceutics|June 8, 2026
Synthesis and Preliminary Evaluation of the <sup>211</sup>At-Labeled PARP Inhibitor [<sup>211</sup>At]Talazoparib as a Targeted Alpha-Particle Emitting TherapeuticYongxiang Zheng, Deyu Kong, Truc T Huynh, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
International Journal of Nanomedicine|November 5, 2021
Gold Nanostars: A Novel Platform for Developing <sup>211</sup>At-Labeled Agents for Targeted Alpha-Particle TherapyYang Liu, Zhengyuan Zhou, Yutian Feng, et al.
Microbiology Resource Announcements|April 3, 2019
Complete Genome Sequence of Halorubrum ezzemoulense Strain Fb21Yutian Feng, Artemis S Louyakis, Andrea M Makkay, et al.
Mbio|April 15, 2024
Using the pan-genomic framework for the discovery of genomic islands in the haloarchaeon <i>Halorubrum ezzemoulense</i>Yutian Feng, Danielle Arsenault, Artemis S Louyakis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 30, 2025
Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [<sup>211</sup>At]YF2Yutian Feng, Truc T Huynh, Yongxiang Zheng, et al.
Nuclear Medicine and Biology|May 4, 2024
PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranosticsTruc T Huynh, Yutian Feng, Rebecca Meshaw, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 10, 2026
First-in-human evaluation of [<sup>211</sup>At]YF2 in patients with metastatic castration-resistant prostate cancerXiaoai Wu, Yongzhao Xiang, Michael R Zalutsky, et al.
Journal of Medicinal Chemistry|November 11, 2022
Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic AgentYutian Feng, Samantha M Sarrett, Rebecca L Meshaw, et al.
Nuclear Medicine and Biology|May 4, 2024
A third generation PSMA-targeted agent [<sup>211</sup>At]YF2: Synthesis and in vivo evaluationYutian Feng, Rebecca L Meshaw, Sean W Finch, et al.
Exploration (Beijing, China)|March 5, 2025
Bioactive scaffolds for tissue engineering: A review of decellularized extracellular matrix applications and innovationsJuan Liu, Qingru Song, Wenzhen Yin, et al.
Molecular Pharmaceutics|June 8, 2026
Synthesis and Preliminary Evaluation of the <sup>211</sup>At-Labeled PARP Inhibitor [<sup>211</sup>At]Talazoparib as a Targeted Alpha-Particle Emitting TherapeuticYongxiang Zheng, Deyu Kong, Truc T Huynh, et al.
Pageof 4